Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
Grant
US12582722B2
Kind: B2
Mar 24, 2026
Assignee
NURIX THERAPEUTICS, INC.
Inventors
Daisuke Kato, Zef Konst, Jeffrey Mihalic, Daniel W. Robbins, Arthur T. Sands
Abstract
The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
CPC Classifications
A61K 47/55
A61K 47/545
A61K 47/54
A61P 35/00
Filing Date
2020-02-04
Application No.
17430721
Claims
21